Recent News

• 09.05.2025 - AHA Hypertension 2025 Poster: Efficacy and Safety of Lorundrostat in Hypertension Patients With High Unmet Medical Need: Subgroup Analyses of the Launch-HTN Trial in Uncontrolled and Treatment-Resistant Hypertension
• 09.05.2025 - Mineralys Therapeutics Presents Subgroup Analyses of Phase 3 Launch-HTN Trial Demonstrating Efficacy and Safety of Lorundrostat in Hypertension Participants with High Unmet Medical Need
• 09.04.2025 - Mineralys Therapeutics Announces Closing of Upsized $287.5 Million Underwritten Public Offering of Common Stock Including Full Exercise of Underwriters’ Option to Purchase Additional Shares
• 09.03.2025 - Mineralys Therapeutics Announces Pricing of Upsized $250.0 Million Underwritten Public Offering of Common Stock
• 09.02.2025 - Mineralys Therapeutics Announces Proposed Public Offering of Common Stock
• 08.12.2025 - Mineralys Therapeutics Reports Second Quarter 2025 Financial Results and Provides Corporate Update
• 08.04.2025 - Mineralys Therapeutics to Announce Second Quarter 2025 Financial Results and Host Conference Call on Tuesday, August 12, 2025

Recent Filings

• 09.03.2025 - 424B5 Prospectus [Rule 424(b)(5)]
• 09.03.2025 - EX-99.1 EX-99.1
• 09.03.2025 - 8-K Current report
• 09.02.2025 - 8-K Current report
• 09.02.2025 - S-3MEF Registration adding securities to prior Form S-3 registration [Rule 462(b)]
• 09.02.2025 - 424B5 Prospectus [Rule 424(b)(5)]
• 08.14.2025 - 4 Statement of changes in beneficial ownership of securities
• 08.14.2025 - SCHEDULE 13G/A Statement of Beneficial Ownership by Certain Investors
• 08.14.2025 - SCHEDULE 13G/A Statement of Beneficial Ownership by Certain Investors
• 08.13.2025 - 144 Report of proposed sale of securities